SCHEMBL4742392

SCHEMBL4742392

Nc1ccc2cc(C=O)c(-c3ccsc3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.46
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
F2 P00734 1/20 0.41
LMNA P02545 1/20 0.41
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
MAOA P21397 1/20 0.41
DRD1 P21728 1/20 0.41
ACHE P22303 1/20 0.41
PTGS1 P23219 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
OPRM1 P35372 1/20 0.41
DRD3 P35462 1/20 0.41
KDR P35968 1/20 0.41
HTT P42858 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4740926 0.81 GPBAR1 (0.59) KMT2AMAOAERN1GPBAR1PDGFRB
SCHEMBL4741461 0.80 ERN1 (0.48) BACE1HTTERN1GPBAR1
SCHEMBL3262682 0.78 CSNK2A2 (0.46) BACE1ERN1GPBAR1PDGFRBPDGFRA
SCHEMBL4871895 0.77 KDM4E (0.52) KMT2AMEN1ADORA3ERN1GPBAR1
SCHEMBL4741927 0.76 GPBAR1 (0.46) BACE1KMT2AMEN1F2LMNA
SCHEMBL4742362 0.74 KDM4E (0.45) BACE1KMT2AMEN1F2LMNA
SCHEMBL4739252 0.73 GPBAR1 (0.55) ERN1GPBAR1PDGFRBPDGFRA
SCHEMBL1880359 0.69 KDR (0.48) KDRERN1ATM
SCHEMBL3261271 0.66 ERN1 (0.36) KMT2AMEN1ADORA3KDRERN1
SCHEMBL4741886 0.65 PDGFRB (0.60) BACE1MAOAGPBAR1PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
WO-2008097976-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-08-14 WO disclosed
WO-2008097976-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE GPR119, GPBAR1, LDLR BACE1 4092/4885KMT2A 4224/4885MEN1 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.